This site is intended for health professionals only

Wednesday 19 June 2019
Share |

Latest News

Lynparza approved for first-line maintenance treatment of BRCA-mutated advanced ovarian cancer

Tuesday 18th June 2019
AstraZeneca and MSD have announced that the European Commission (EC) has approved Lynparza (olaparib) as a 1st-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer.
The licensed indication is as a maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (...
Thu, 9 May 2019
Familial chylomicronaemia syndrome is a debilitating disease caused by impaired function of the enzyme lipoprotein lipase, which causes high circulating levels of triglycerides in the body, leading to extreme abdominal pain and episodes of potentially fatal pancreatitis
Thu, 2 May 2019
Crohn’s & Colitis UK announces targeted research call into pain, one of the most debilitating symptoms of these conditions
Thu, 2 May 2019
The prospect of a CT scan can be scary for a child, but one student from the University of Salford in the UK is aiming to change that with her new business, ‘Stick with It’
Thu, 2 May 2019
Clinical Fellow Ben Shelley is driving forward the chronic pain trial at the Golden Jubilee Hospital in Scotland
Thu, 2 May 2019
Pancreatic Cancer UK has announced that they are investing £750,000 into developing the first simple test for pancreatic cancer by 2024
Thu, 2 May 2019
A de-escalation strategy omitting chemotherapy in the first line treatment of HER2 positive metastatic breast cancer was attempted in the PERNETTA trial
Mon, 29 Apr 2019
All opioid medicines in the UK will now carry addiction warnings on their labels, the health secretary has announced.